Search Results

CereVasc, Inc. announced today that it has received approval from the US Food and Drug Administration (FDA) to initiate its “Pivotal Study to Evaluate the Safety and Effectiveness of the CereVasc® eShunt® System in the Treatment of Normal Pressure Hydrocephalus” (STRIDE trial).

CereVasc, Inc., a clinical-stage, medical device company developing novel treatments for neurological diseases, announced it has successfully completed the initial closing of a $70 Million Series B financing.

CereVasc, Inc. announced that data from its clinical studies in the United States and Argentina, examining the use of its eShunt System to treat communicating hydrocephalus, was presented at the ABC WIN Seminar in Val d’Isere.

CereVasc, Inc. announced that Dr. Pedro Lylyk, Director General of ENERI, will deliver a symposium presentation entitled, “Endovascular Shunting for Hydrocephalus After Subarachnoid Hemorrhage and Other Applications,” at the International Stroke Conference in Phoenix, Arizona on Wednesday, February 7th.

CereVasc, Inc. and LianMedical announced a partnership focused on bringing CereVasc’s eShunt® System and related products to patients and providers in China, Hong Kong, Taiwan, and Macaw.

CereVasc, Inc. announced that data from clinical studies examining the use of its eShunt System to treat elderly patients with normal pressure hydrocephalus and patients with communicating hydrocephalus following treatment for a ruptured cerebral aneurysm, was recently presented at the Congress of Neurological Surgeons (CNS) Annual Meeting in Washington, DC.